Evidence map›Paper›PMID 28082341›Full record

ArticleHaematologica2017

The transcription factor GATA1 regulates NBEAL2 expression through a long-distance enhancer.

Anouck Wijgaerts, Christine Wittevrongel, Chantal Thys, Timothy Devos, Kathelijne Peerlinck, Marloes R Tijssen, Chris Van Geet, Kathleen Freson

Abstract read
In one paragraph

Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anouck WijgaertsDepartment of Cardiovascular Sciences, Center for Molecular and Vascular Biology, KULeuven, Belgium.
Christine WittevrongelDepartment of Cardiovascular Sciences, Center for Molecular and Vascular Biology, KULeuven, Belgium.
Chantal ThysDepartment of Cardiovascular Sciences, Center for Molecular and Vascular Biology, KULeuven, Belgium.
Timothy DevosDepartment of Haematology, University Hospitals Leuven, Belgium.
Kathelijne PeerlinckDepartment of Cardiovascular Sciences, Center for Molecular and Vascular Biology, KULeuven, Belgium.
Marloes R TijssenNHS Blood and Transplant, Cambridge Biomedical Campus, UK.
Chris Van GeetDepartment of Cardiovascular Sciences, Center for Molecular and Vascular Biology, KULeuven, Belgium.
Kathleen FresonDepartment of Cardiovascular Sciences, Center for Molecular and Vascular Biology, KULeuven, Belgium kathleen.freson@med.kuleuven.be.

Funding

British Heart Foundation PG/13/77/30375
6 · The paper itself

Abstract

Gray platelet syndrome is named after the gray appearance of platelets due to the absence of α-granules. It is caused by recessive mutations in

Indexed as

Enhancer Elements, GeneticGene Expression RegulationAllelesBlood PlateletsBlood ProteinsCell DifferentiationGATA1 Transcription FactorGene ExpressionGenes, RecessiveGenes, ReporterGenes, X-LinkedGenetic Association StudiesGenetic Predisposition to DiseaseHomozygoteHumansMegakaryocytesBlood ProteinsGATA1 Transcription FactorNBEAL2 protein, humanRNA, Small Interfering

Identifiers

PMID28082341
PMCPMC5395110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.